Literature DB >> 11704083

Randomized trial of oral versus vaginal misoprostol at one day after mifepristone for early medical abortion.

E A Schaff1, S L Fielding, C Westhoff.   

Abstract

Mifepristone was recently approved in the United States. Regimens with shorter intervals may be more acceptable. The objective of this study was to determine whether the oral route of misoprostol was as effective as the vaginal route of misoprostol 1 day after mifepristone. A prospective, open-labeled, randomized trial of healthy adult women up to 63 days pregnant and wanting a medical abortion were randomized to use either two doses of oral misoprostol 400 microg taken 2 h apart or misoprostol 800 microg vaginally. Women self-administered misoprostol 1 day after taking one-third of the standard dose of mifepristone (200 mg) orally. Women then returned to the clinic up to 5 days later for a repeat sonogram evaluation. A dose of vaginal misoprostol was administered to women with a continuing pregnancy who then returned 1 day later to Day 15. The primary outcome measures were a complete medical abortion by the first or by the second follow-up visits. Surgical intervention was indicated for continuing pregnancy at the second follow-up visit, excessive bleeding, or persistent products of conception 5 weeks later. One thousand one hundred sixty-eight women were enrolled. Of the 1144 (98%) women who complied with their random assignment, two oral doses of misoprostol (800 microg total) were 90% effective at inducing an abortion by the first follow-up visit, compared with one dose of misoprostol by vagina of 97% (chi(2) = 23.95, p = 0.001). By the second follow-up visit, the complete abortion rate was 95% for oral misoprostol and 99% for vaginal misoprostol (chi(2) = 21.76, p = 0.001). There were minimal differences in side effects. Women preferred the oral route. The trial demonstrated that although two doses of oral misoprostol were effective, the vaginal misoprostol was more effective at inducing an early medical abortion at 1 day after low-dose mifepristone, and the regimen could be extended to 63 days gestation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11704083     DOI: 10.1016/s0010-7824(01)00229-3

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  9 in total

1.  Knowledge of medication abortion among adolescent medicine providers.

Authors:  Mandy S Coles; Kevin K Makino; Rachael Phelps
Journal:  J Adolesc Health       Date:  2011-10-14       Impact factor: 5.012

2.  Medical Abortion-An Alternative to Surgical Abortion.

Authors:  K Kapur; G S Joneja; M Biswas
Journal:  Med J Armed Forces India       Date:  2011-07-21

3.  Efficacy and safety of medical abortion using mifepristone and buccal misoprostol through 63 days.

Authors:  Mary Gatter; Kelly Cleland; Deborah L Nucatola
Journal:  Contraception       Date:  2015-01-13       Impact factor: 3.375

Review 4.  Medical methods for first trimester abortion.

Authors:  Jing Zhang; Kunyan Zhou; Dan Shan; Xiaoyan Luo
Journal:  Cochrane Database Syst Rev       Date:  2022-05-24

5.  Factors related to successful misoprostol treatment for early pregnancy failure.

Authors:  Mitchell D Creinin; Xiangke Huang; Carolyn Westhoff; Kurt Barnhart; Jerry M Gilles; Jun Zhang
Journal:  Obstet Gynecol       Date:  2006-04       Impact factor: 7.661

Review 6.  Medical methods for first trimester abortion.

Authors:  Regina Kulier; Nathalie Kapp; A Metin Gülmezoglu; G Justus Hofmeyr; Linan Cheng; Aldo Campana
Journal:  Cochrane Database Syst Rev       Date:  2011-11-09

7.  Effectiveness and safety of sublingual misoprostol in medical treatment of the 1st trimester miscarriage: experience of off-label use in Korea.

Authors:  Jung Yeon Park; Hyo Jeong Ahn; Ba Raem Yoo; Kyu Ri Hwang; Taek Sang Lee; Hye Won Jeon; Sun Min Kim; Byoung Jae Kim
Journal:  Obstet Gynecol Sci       Date:  2018-03-02

8.  Medical termination for pregnancy in early first trimester (≤ 63 days) using combination of mifepristone and misoprostol or misoprostol alone: a systematic review.

Authors:  Ferid A Abubeker; Antonella Lavelanet; Maria I Rodriguez; Caron Kim
Journal:  BMC Womens Health       Date:  2020-07-07       Impact factor: 2.809

9.  Comparison of Outcomes before and after Ohio's Law Mandating Use of the FDA-Approved Protocol for Medication Abortion: A Retrospective Cohort Study.

Authors:  Ushma D Upadhyay; Nicole E Johns; Sarah L Combellick; Julia E Kohn; Lisa M Keder; Sarah C M Roberts
Journal:  PLoS Med       Date:  2016-08-30       Impact factor: 11.069

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.